NASDAQ:MGEN - Miragen Therapeutics News Headlines

Sign in or create an account to add this stock to your watchlist.
$3.02 -0.15 (-4.73 %)
(As of 01/21/2019 06:51 AM ET)
Previous Close$3.17
Today's Range$2.93 - $3.2143
52-Week Range$2.20 - $8.94
Volume305,575 shs
Average Volume328,168 shs
Market Capitalization$93.14 million
P/E Ratio-2.19
Dividend YieldN/A
Beta1.36

Headlines

Miragen Therapeutics (NASDAQ MGEN) News Headlines

Source:
DateHeadline
Miragen Therapeutics Inc to Post FY2023 Earnings of $0.13 Per Share, Wedbush Forecasts (MGEN)Miragen Therapeutics Inc to Post FY2023 Earnings of $0.13 Per Share, Wedbush Forecasts (MGEN)
www.americanbankingnews.com - January 15 at 8:22 AM
Miragen Therapeutics Inc (MGEN) Receives Consensus Rating of "Buy" from AnalystsMiragen Therapeutics Inc (MGEN) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - January 15 at 8:14 AM
Miragen Therapeutics Inc (MGEN) Expected to Announce Quarterly Sales of $1.54 MillionMiragen Therapeutics Inc (MGEN) Expected to Announce Quarterly Sales of $1.54 Million
www.americanbankingnews.com - January 15 at 4:26 AM
Zacks: Analysts Anticipate Miragen Therapeutics Inc (MGEN) to Announce -$0.31 EPSZacks: Analysts Anticipate Miragen Therapeutics Inc (MGEN) to Announce -$0.31 EPS
www.americanbankingnews.com - January 13 at 5:15 AM
MiRagens cobomarsen shows positive action in early-stage blood cancer studiesMiRagen's cobomarsen shows positive action in early-stage blood cancer studies
seekingalpha.com - January 10 at 3:12 PM
miRagen Announces New Clinical Data in Patients With Three Different Types of Blood Cancers Treated With CobomarsenmiRagen Announces New Clinical Data in Patients With Three Different Types of Blood Cancers Treated With Cobomarsen
finance.yahoo.com - January 10 at 3:12 PM
Miragen Therapeutics Inc.Miragen Therapeutics Inc.
www.barrons.com - January 4 at 3:17 PM
Miragen Therapeutics (MGEN) Research Coverage Started at Robert W. BairdMiragen Therapeutics (MGEN) Research Coverage Started at Robert W. Baird
www.americanbankingnews.com - January 4 at 9:11 AM
Miragen Therapeutics (MGEN) Now Covered by B. RileyMiragen Therapeutics (MGEN) Now Covered by B. Riley
www.americanbankingnews.com - December 31 at 7:40 AM
miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma and Cutaneous T-Cell Lymphoma at the 11th Annual T-Cell Lymphoma ForummiRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma and Cutaneous T-Cell Lymphoma at the 11th Annual T-Cell Lymphoma Forum
finance.yahoo.com - December 20 at 3:13 PM
Hedge Funds Are Crazy About Miragen Therapeutics, Inc. (MGEN)Hedge Funds Are Crazy About Miragen Therapeutics, Inc. (MGEN)
finance.yahoo.com - December 18 at 3:05 PM
miRagen Therapeutics Announces Board of Director Evolution and Appointment of New ChairmanmiRagen Therapeutics Announces Board of Director Evolution and Appointment of New Chairman
finance.yahoo.com - December 6 at 5:16 AM
Form 8-K MIRAGEN THERAPEUTICS, For: Dec 02 - StreetInsider.comForm 8-K MIRAGEN THERAPEUTICS, For: Dec 02 - StreetInsider.com
www.streetinsider.com - December 5 at 3:14 PM
miRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From PhasemiRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From Phase
www.nasdaq.com - December 3 at 5:16 AM
Miragen Therapeutics, Inc. (MGEN) CEO William Marshall on Q3 2018 Results - Earnings Call TranscriptMiragen Therapeutics, Inc. (MGEN) CEO William Marshall on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 10 at 5:15 AM
Form 10-Q MIRAGEN THERAPEUTICS, For: Sep 30Form 10-Q MIRAGEN THERAPEUTICS, For: Sep 30
www.streetinsider.com - November 9 at 3:14 PM
miRagen Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate UpdatemiRagen Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - November 8 at 5:37 AM
Signal Genetics, Inc. (MGEN) Reports Q3 Loss, Misses Revenue EstimatesSignal Genetics, Inc. (MGEN) Reports Q3 Loss, Misses Revenue Estimates
finance.yahoo.com - November 8 at 5:37 AM
Miragen Therapeutics to Present New Cobomarsen Phase 1 Clinical Trial Data at the 2018 American Society of Hematology Annual MeetingMiragen Therapeutics to Present New Cobomarsen Phase 1 Clinical Trial Data at the 2018 American Society of Hematology Annual Meeting
finance.yahoo.com - November 1 at 3:08 PM
miRagen Therapeutics to Present at two Investor Conferences in November 2018miRagen Therapeutics to Present at two Investor Conferences in November 2018
finance.yahoo.com - October 29 at 9:35 AM
miRagen Therapeutics to Report Third Quarter 2018 Financial Results and Host Conference Call on November 7, 2018miRagen Therapeutics to Report Third Quarter 2018 Financial Results and Host Conference Call on November 7, 2018
finance.yahoo.com - October 24 at 3:09 PM
miRagen Therapeutics (MGEN) Highlights Data from Preclinical Studies Demonstrating the Potential Anti-Fibrotic Effect of Remlarsen in the CorneamiRagen Therapeutics (MGEN) Highlights Data from Preclinical Studies Demonstrating the Potential Anti-Fibrotic Effect of Remlarsen in the Cornea
www.streetinsider.com - October 2 at 3:06 PM
miRagen Therapeutics Announces the Presentation of Data From Preclinical Studies Demonstrating the Potential Anti-Fibrotic Effect of Remlarsen in the Cornea at the 2018 OLIGO Meeting in Seattle, WAmiRagen Therapeutics Announces the Presentation of Data From Preclinical Studies Demonstrating the Potential Anti-Fibrotic Effect of Remlarsen in the Cornea at the 2018 OLIGO Meeting in Seattle, WA
finance.yahoo.com - October 1 at 3:02 PM
Miragen Therapeutics (MGEN) Presents At 2018 Wedbush PacGrow Healthcare Conference - SlideshowMiragen Therapeutics (MGEN) Presents At 2018 Wedbush PacGrow Healthcare Conference - Slideshow
seekingalpha.com - August 15 at 3:08 PM
Miragen Therapeutics, Inc. (MGEN) CEO William Marshall on Q2 2018 Results - Earnings Call TranscriptMiragen Therapeutics, Inc. (MGEN) CEO William Marshall on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - August 8 at 5:11 AM
miRagen Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate UpdatemiRagen Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - August 8 at 5:11 AM
miRagen Therapeutics and The Leukemia & Lymphoma Society® Enter Into an Agreement to Facilitate the Development of Cobomarsen in Cutaneous T-Cell LymphomamiRagen Therapeutics and The Leukemia & Lymphoma Society® Enter Into an Agreement to Facilitate the Development of Cobomarsen in Cutaneous T-Cell Lymphoma
finance.yahoo.com - August 6 at 3:06 PM
miRagen Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare ConferencemiRagen Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - July 31 at 3:08 PM
miRagen Therapeutics to Report Second Quarter 2018 Financial Results and Host Conference Call on August 7, 2018miRagen Therapeutics to Report Second Quarter 2018 Financial Results and Host Conference Call on August 7, 2018
finance.yahoo.com - July 25 at 3:05 PM
MiRagen launches mid-stage study of MRG-201MiRagen launches mid-stage study of MRG-201
seekingalpha.com - July 10 at 3:12 PM
miRagen Therapeutics Announces Initiation of Phase 2 Clinical Trial of MRG-201miRagen Therapeutics Announces Initiation of Phase 2 Clinical Trial of MRG-201
finance.yahoo.com - July 10 at 3:12 PM
Gaithersburg biotech raising $1M to stop cancer tumors in their tracksGaithersburg biotech raising $1M to stop cancer tumors in their tracks
finance.yahoo.com - July 3 at 3:05 PM
Miragen Therapeutics to Present First Cobomarsen Phase 1 Clinical Trial Data From Patients With Adult T-Cell Leukemia/lymphoma and New Interim Data From Patients With Mycosis Fungoides at the 2018 American Society of Clinical Oncology Annual MeetingMiragen Therapeutics to Present First Cobomarsen Phase 1 Clinical Trial Data From Patients With Adult T-Cell Leukemia/lymphoma and New Interim Data From Patients With Mycosis Fungoides at the 2018 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - June 4 at 3:05 PM
miRagen Therapeutics to Present at Jefferies 2018 Global Healthcare Conference on Thursday, June 7thmiRagen Therapeutics to Present at Jefferies 2018 Global Healthcare Conference on Thursday, June 7th
finance.yahoo.com - May 31 at 3:01 PM
Miragen Therapeutics (MGEN) Presents At 2018 UBS Global Healthcare Conference - SlideshowMiragen Therapeutics (MGEN) Presents At 2018 UBS Global Healthcare Conference - Slideshow
seekingalpha.com - May 25 at 3:12 PM
miRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American ...miRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American ...
globenewswire.com - May 18 at 5:04 AM
miRagen Therapeutics (MGEN) to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at ASCOmiRagen Therapeutics (MGEN) to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at ASCO
www.streetinsider.com - May 18 at 5:04 AM
FDA Thumbs-Down Makes EOLS Frown, IMMU Up On Breast Cancer Data, MGEN On WatchFDA Thumbs-Down Makes EOLS Frown, IMMU Up On Breast Cancer Data, MGEN On Watch
www.nasdaq.com - May 17 at 5:31 AM
miRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American Society of Clinical Oncology Annual MeetingmiRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - May 17 at 5:31 AM
miRagen Therapeutics (MGEN) CEO William Marshall on Q1 2018 Results - Earnings Call TranscriptmiRagen Therapeutics' (MGEN) CEO William Marshall on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 5:01 AM
miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate UpdatemiRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 10 at 5:01 AM
Should Miragen Therapeutics Inc’s (NASDAQ:MGEN) Recent Earnings Decline Worry You?Should Miragen Therapeutics Inc’s (NASDAQ:MGEN) Recent Earnings Decline Worry You?
finance.yahoo.com - May 9 at 5:09 AM
miRagen Therapeutics Announces New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis FungoidesmiRagen Therapeutics Announces New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis Fungoides
finance.yahoo.com - May 9 at 5:09 AM
miRagen Therapeutics (MGEN) Reports Initiation of Second Phase 1 Clinical Trial of MRG-110miRagen Therapeutics (MGEN) Reports Initiation of Second Phase 1 Clinical Trial of MRG-110
www.streetinsider.com - May 4 at 3:13 PM
miRagen Therapeutics to Report First Quarter 2018 Financial Results and Host Conference Call on May 9, 2018miRagen Therapeutics to Report First Quarter 2018 Financial Results and Host Conference Call on May 9, 2018
finance.yahoo.com - May 2 at 3:10 PM
Second early-stage study of miRagens MRG-110 on goSecond early-stage study of miRagen's MRG-110 on go
seekingalpha.com - May 1 at 3:02 PM
miRagen Therapeutics Announces Initiation of Second Phase 1 Clinical Trial of MRG-110miRagen Therapeutics Announces Initiation of Second Phase 1 Clinical Trial of MRG-110
finance.yahoo.com - May 1 at 3:01 PM
miRagen Therapeutics Announces New Data Showing Administration of MRG-110 Improved Tissue PerfusionmiRagen Therapeutics Announces New Data Showing Administration of MRG-110 Improved Tissue Perfusion
www.nasdaq.com - April 27 at 3:02 PM
miRagen Therapeutics (MGEN) Say Data Shows Administration of MRG-110 Improved Tissue Perfusion and Wound Healing in Late Stage Preclinical StudiesmiRagen Therapeutics (MGEN) Say Data Shows Administration of MRG-110 Improved Tissue Perfusion and Wound Healing in Late Stage Preclinical Studies
www.streetinsider.com - April 27 at 3:02 PM
miRagen Therapeutics Announces New Data Showing Administration of MRG-110 Improved Tissue Perfusion and Wound Healing in Late Stage Preclinical StudiesmiRagen Therapeutics Announces New Data Showing Administration of MRG-110 Improved Tissue Perfusion and Wound Healing in Late Stage Preclinical Studies
finance.yahoo.com - April 27 at 3:02 PM
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel